rmdopen.bmj3d
Frailty is independently associated with subclinical cardiovascular disease in patients with systemic lupus erythematosus
Objectives Cardiovascular disease is a leading cause of mortality in systemic lupus erythematosus (SLE). Frailty has been ...
rmdopen.bmj1d
Earlier is better when treating rheumatoid arthritis: but can we detect a window of opportunity?
Objectives The window of opportunity (WOO) hypothesis suggests a limited time frame to stop rheumatoid arthritis (RA). We hypothesised that a WOO could either be represented by a hyperbolic (‘curved’) ...
rmdopen.bmj3d
Anifrolumab: the new frontier in the treatment of genetic interferonopathies
Understanding the precise mechanisms of monogenic autoinflammatory diseases provides crucial insights into the complex pathophysiology of more common multifactorial diseases, while treatments ...
rmdopen.bmj13d
Window of opportunity in rheumatoid arthritis – definitions and supporting evidence: from old to new perspectives
The therapeutic window of opportunity in rheumatoid arthritis (RA) is often referred to. However, some have questioned whether such a period, in which the disease is more susceptible to ...
rmdopen.bmj13d
Impact of filgotinib on pain control in the phase 3 FINCH studies
Present affiliation The present affiliation of Shangbang Rao is: Candel Therapeutics, Needham, MA, USA Present affiliation The present affiliation of Pieter-Jan Stiers is: AgomAb Therapeutics, Ghent, ...
rmdopen.bmj2d
Genes deregulated in giant cell arteritis by Nanostring nCounter gene expression profiling in temporal artery biopsies
Objective To identify differentially expressed genes in temporal artery biopsies (TABs) from patients with giant cell arteritis (GCA) with different histological patterns of inflammation: transmural ...
rmdopen.bmj8d
Immune responses to mRNA vaccines against SARS-CoV-2 in patients with immune-mediated inflammatory rheumatic diseases
Background Patients with immune-mediated rheumatic diseases (IMRDs) are commonly treated with immunosuppressors and prone to infections. Recently introduced mRNA SARS-CoV-2 vaccines have demonstrated ...
rmdopen.bmj6d
Efficacy and safety of filgotinib in methotrexate-naive patients with rheumatoid arthritis with poor prognostic factors: post hoc analysis of FINCH 3
Objective This analysis evaluated efficacy and safety of filgotinib, a Janus-associated kinase 1-preferential inhibitor, in methotrexate (MTX)-naive patients with rheumatoid arthritis (RA) with ...
rmdopen.bmj4d
Efficacy of tofacitinib monotherapy in methotrexate-naive patients with early or established rheumatoid arthritis
Introduction Tofacitinib is an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis (RA). Tofacitinib monotherapy was previously shown to inhibit structural damage, reduce clinical ...
rmdopen.bmj5d
Comparative early effectiveness across 14 PsA drugs and 5 classes of PsA treatment: 3-month results from the PRO-SPIRIT study
We will not keep your email address; we ask for it so your friend knows the email isn't spam.
rmdopen.bmj9d
From patients with arthralgia, pre-RA and recently diagnosed RA: what is the current status of understanding RA pathogenesis?
It is believed that therapy for rheumatoid arthritis (RA) is the most effective and beneficial within a short time frame around RA diagnosis. This insight has caused a shift from research in patients ...